What is claimed is:

1. An isolated human antibody or antibody fragment comprising one or more complementarity determining regions selected from the group consisting of SEQ ID NO:2 at CDRH1; SEQ ID NO:4 at CDRH2; SEQ ID NO:6 at CDRH3; SEQ ID NO:10 at CDRL1; SEQ ID NO:12 at CDRL2; and SEQ ID NO:14 at CDRL3.

2. The antibody or antibody fragement of Claim 1, which comprises SEQ ID NO:2 at CDRH1; SEQ ID NO:4 at CDRH2; and SEQ ID NO:6 at CDRH3.

3. The antibody or antibody fragement of Claim 1, which comprises SEQ ID NO:8.

4. The antibody or antibody fragement of Claim 1, which comprises SEQ ID NO:10 at CDRL1; SEQ ID NO:12 at CDRL2; and SEQ ID NO:14 at CDRL3.

5. The antibody or antibody fragement of Claim 1, which comprises SEQ ID NO:16.

6. The antibody or antibody fragment of Claim 1, which comprises SEQ ID NO:2 at CDRH1; SEQ ID NO:4 at CDRH2; SEQ ID NO:6 at CDRH3; SEQ ID NO:10 at CDRL1; SEQ ID NO:12 at CDRL2; and SEQ ID NO:14 at CDRL3.

7. The antibody or antibody fragment of Claim 1, which comprises SEQ ID NO:8 and SEQ ID NO:16.

8. The antibody or antibody fragment of any one of Claims 1 to 7, which binds selectively to EGFR.

9. The antibody or antibody fragment of any one of Claims 1 to 7, which inhibits binding of EGFR to a ligand of EGFR.

10. The antibody or antibody fragment of any one of Claims 1 to 7, which neutralizes EGFR.

11. The antibody fragment of any one of Claims 1 to 7, which is selected from the group consisting of a single chain antibody, an Fab, a single chain Fv, a diabody, and a triabody.

12. A conjugate of the antibody or antibody fragment of any one of Claims 1 to 7.

13. The conjugate of Claim 12, which comprises an anti-neoplastic agent, a target moiety or a reporter moiety.

14. An isolated polynucleotide which encodes an antibody or antibody fragment and comprises one or more nucleotide sequences selected from the group consisting of SEQ ID NO: 1 at CDRH1; SEQ ID NO:3 at CDRH2; SEQ ID NO:5 at CDRH3; SEQ ID NO:9 at CDRL1; SEQ ID NO:11 at CDRL2; and SEQ ID NO:13 at CDRL3.

15. The isolated polynucleotide of Claim 14, which comprises SEQ ID NO:7.

16. The isolated polynucleotide of Claim 14, which comprises SEQ ID NO:15.

17. An expression vector comprising the polynucleotide of any one of Claims 14 to 16.

18. A recombinant host cell comprising the expression vector of Claim 17.

19. The recombinant host cell of Claim 18 which produces a polypeptide comprising SEQ ID NO:8 and a polypeptide comprising SEQ ID NO:16.

20. The recombinant host cell of Claim 18 which produces a polypeptide comprising SEQ ID NO:8 and SEQ ID NO:16.

21. A method of inhibiting tumor growth in a mammal comprising administering a therapeutically effective amount of the antibody of any one of Claims 1 to 11.

22. The method of Claim 21, wherein the tumor expresses EGFR.

23. The method of Claim 21, wherein the tumor overexpresses EGFR.

24. The method of Claim 21, wherein the tumor is a primary tumor.

25. The method of Claim 21, wherein the tumor is a metastatic tumor.

26. The method of Claim 21, wherein the tumor is a refractory tumor.

27. The method of Claim 21, wherein the tumor is a vascularized tumor.

28. The method of Claim 21, wherein the tumor is selected from the group consisting of a colorectal tumor, a head and neck tumor, a pancreatic tumor, a lung tumor, a breast tumor, a renal cell carcinoma, and a glioblastoma.

29. The method of Claim 21, wherein the antibody or antibody fragment is administered in combination with an anti-neoplastic agent.

30. The method of Claim 29, wherein the antineoplastic agent is a chemotherapeutic agent.

31. The method of Claim 29, wherein the antineoplastic agent is irinotecan (CPT-11).

32. The method of Claim 29, wherein the antineoplastic agent is radiation.

33. The method of Claim 21, wherein the antibody or antibody fragment is administered with an EGFR antagonist.

34. The method of Claim 33, wherein the EGFR antagonist is an intracellular EGFR antagonist.

35. The method of Claim 21, which further comprises administration of a therapeutically effective amount of a vascular endothelial factor receptor (VEGFR) antagonist.

36. The method of Claim 21, which further comprises administration of a therapeutically effective amount of an insulin like growth factor receptor (IGFR) antagonist.

37. A method of treating a hyperproliferative disease comprising administering a therapeutically effective amount of an antibody of any one of Claims 1 to 11.

38. The method of Claim 37, wherein the hyperproliferative disease is psoriasis.

39. The method of Claim 38, wherein the antibody or antibody fragment is administered in combination with a topical or systemic agent for psoriasis

40. The method of Claim 38, wherein the antibody or antibody fragment is administered in combination with a corticosteroid.

41. The method of Claim 38, wherein the antibody of antibody fragment is administered in combination with a retinoid.